Payment overview · 2025
General Payments
$240.66
11 reported records · 3 companies
Healthcare provider profile · identity verified
Stuart Larry Saftchick, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BRONX, NY · NPI 1194731950
Verified facts
What the public records show
CMS Open Payments records show Stuart Larry Saftchick, M.D. received $240.66 in general payments during 2025 across 11 reported records.
Exact Sciences Corporation accounted for 64.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $155.14 | 64.5% | 7 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $59.25 | 24.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $26.27 | 10.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $240.66 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $96.77 | 5 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $59.25 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $58.37 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $26.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 696 | 127 |
| Amlodipine Besylate | Amlodipine Besylate | 538 | 81 |
| Famotidine | Famotidine | 439 | 40 |
| Gabapentin | Gabapentin | 395 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 307 | 35 |
| Lisinopril | Lisinopril | 303 | 37 |
| Metformin Hcl | Metformin Hcl | 265 | 56 |
| Mirtazapine | Mirtazapine | 259 | 26 |
| Losartan Potassium | Losartan Potassium | 218 | 58 |
| Eliquis | Apixaban | 217 | 20 |
| Levetiracetam | Levetiracetam | 214 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 214 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 211 | 34 |
| Sertraline Hcl | Sertraline Hcl | 194 | 20 |
| Trazodone Hcl | Trazodone Hcl | 193 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 180 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 176 | 26 |
| Baclofen | Baclofen | 174 | 13 |
| Furosemide | Furosemide | 174 | 25 |
| Memantine Hcl | Memantine Hcl | 169 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 22 |
| Nifedipine Er | Nifedipine | 166 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 155 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 153 | 20 |
| Omeprazole | Omeprazole | 150 | 42 |
| Carvedilol | Carvedilol | 145 | 18 |
| Buspirone Hcl | Buspirone Hcl | 144 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 121 | 21 |
| Jardiance | Empagliflozin | 113 | 19 |
| Donepezil Hcl | Donepezil Hcl | 103 | 11 |
| Simvastatin | Simvastatin | 101 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 30 |
| Enalapril Maleate | Enalapril Maleate | 94 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 92 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 88 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 85 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 77 | 22 |
| Latanoprost | Latanoprost | 76 | 12 |
| Potassium Chloride | Potassium Chloride | 76 | 13 |
| Linzess | Linaclotide | 72 | suppressed |
| Ezetimibe | Ezetimibe | 68 | 11 |
| Divalproex Sodium | Divalproex Sodium | 66 | suppressed |
| Tradjenta | Linagliptin | 66 | suppressed |
| Chlorthalidone | Chlorthalidone | 65 | 15 |
| Valsartan | Valsartan | 65 | 14 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 60 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 60 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 55 | suppressed |
| Trulicity | Dulaglutide | 55 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 52 | suppressed |
| Januvia | Sitagliptin Phosphate | 50 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 47 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 41 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 35 | suppressed |
| Gemtesa | Vibegron | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Meloxicam | Meloxicam | 33 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 31 | suppressed |
| Risperidone | Risperidone | 31 | suppressed |
| Amantadine | Amantadine Hcl | 30 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 30 | suppressed |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Humulin R | Insulin Regular, Human | 28 | suppressed |
| Fluocinonide | Fluocinonide | 27 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Silodosin | Silodosin | 27 | suppressed |
| Perphenazine | Perphenazine | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Loperamide | Loperamide Hcl | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Ssd | Silver Sulfadiazine | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Haloperidol | Haloperidol | 17 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 17 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 17 | suppressed |
| Rexulti | Brexpiprazole | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 12 |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Veo Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $240.66 · 11 records | Exact Sciences Corporation | Cologuard Collection Kit, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, XIFAXAN | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error